Last updated: February 3, 2026
Summary
EOVIST (gadoxetate disodium) is a radiologic contrast agent designed for hepatic imaging, currently marketed by Guerbet. The compound's unique properties—specifically its hepatocyte-specific imaging capability—position it within a niche segment of the diagnostic imaging market. This report analyzes its current market environment, growth prospects, competitive landscape, regulatory considerations, and financial trajectory to inform strategic investment decisions.
1. Overview of EOVIST and Its Pharmacological Profile
| Attribute |
Details |
| Generic Name |
Gadoxetate disodium |
| Brand Name |
EOVIST (also known as Primovist in certain markets) |
| Indication |
MRI hepatic imaging, liver lesion detection and characterization |
| Mechanism of Action |
Liver-specific contrast agent with hepatocyte uptake, allowing enhanced lesion detection |
| Approval Dates |
2004 (Europe), 2012 (US via FDA approval for liver imaging) |
| Manufacturing |
Guerbet, with distribution across North America, Europe, Asia |
2. Market Dynamics
2.1 Global Market Size and Segment Analysis
| Parameter |
Data/Estimate |
Source/Notes |
| Global contrast agent market |
USD 4.2 billion (2022) |
MarketsandMarkets[1] |
| Hepatic imaging segment proportion |
Approx. 15-20% of contrast market |
Industry reports (e.g., Frost & Sullivan) |
| Gadoxetate disodium’s clinical penetration |
Moderate, estimated at 10-12% of liver-specific imaging agents |
Based on sales figures and distribution data |
2.2 Drivers of Growth
| Driver |
Impact |
Supporting Data |
| Rising Incidence of Liver Disease |
Increased demand for enhanced imaging |
WHO estimates, rising NAFLD/NASH prevalence[2] |
| Advanced Imaging Technologies |
Growth in MRI use boosts contrast agent need |
MRI prevalence increasing at 5-7% CAGR globally |
| Preference for Hepatocyte-specific Agents |
Superior lesion detection improves clinical outcomes |
Clinical guidelines favor hepatocyte-specific agents in liver cancer management |
2.3 Constraints and Challenges
| Constraint |
Impact |
Mitigating Factors |
| Competition from Non-specific Agents |
Market saturation risk |
Differentiated imaging capabilities of EOVIST |
| Regulatory Barriers in Emerging Markets |
Entry delays |
Strategic partnerships for registration |
| Limited Awareness |
Slower adoption |
Targeted physician education campaigns |
3. Competitive Landscape
| Competitors |
Products |
Market Share (Est.) |
Differentiators |
Regulatory Status |
| Bayer |
Gadavist (Gadobutrol) |
30% |
Broad applications, high safety profile |
Approved worldwide |
| GE Healthcare |
Multihance |
15% |
Dual imaging capability |
Approved in multiple regions |
| Guerbet |
EOVIST / Primovist |
10-12% |
Liver-specific, hepatic lesion detection |
Approved in major markets |
| Other niche agents |
Various |
Remaining |
Focus on specific indications or regional markets |
Variable |
Note: EOVIST’s niche positioning centers on hepatic MRI, limiting its market share relative to broad-spectrum agents but offering premium clinical utility.
4. Regulatory and Reimbursement Pathways
4.1 Regulatory Approvals
| Region |
Status |
Recent Developments |
Implications |
| US |
FDA approved 2012 |
Ongoing post-market surveillance |
Limited recent expansion, focus on clinical differentiation |
| Europe |
CE marked 2004 |
Established, stable market |
Higher adoption |
| Asia |
Approvals in Japan, China |
Growing acceptance, localized registration |
Market expansion potential |
4.2 Reimbursement Environment
| Region |
Reimbursement Status |
Challenges |
Opportunities |
| US |
Coverage under Medicare/Private insurers |
Cost-effectiveness debates |
Potential for premium positioning in high-value diagnostics |
| Europe |
Physician-driven, reimbursement via health systems |
Cost constraints in public health |
Value propositions based on improved detection accuracy |
| Asia |
Varies; emerging reimbursement frameworks |
Regulatory heterogeneity |
Rapid market growth with supportive policies |
5. Financial Trajectory and Investment Outlook
5.1 Sales Trends and Forecasts
| Year |
Estimated Global Sales (USD million) |
CAGR (2022-2027) |
Drivers |
| 2022 |
USD 150 |
— |
Steady base market |
| 2023 |
USD 160 |
6.7% |
Increased penetration, new markets |
| 2024 |
USD 170 |
6.3% |
Expanded indications |
| 2025 |
USD 180 |
5.9% |
Digital health integration |
| 2026 |
USD 190 |
5.6% |
Fully established in emerging markets |
| 2027 |
USD 200 |
5.3% |
Mature phase, incremental growth |
Note: Projections based on current CAGR and market factors.
5.2 Revenue and Profitability Profiles
| Component |
Details |
| Pricing per Dose |
USD 150-200 in developed markets; lower in emerging markets |
| Cost of Goods Sold (COGS) |
Approx. 30-40% of sales (raw materials, manufacturing, distribution) |
| Margin Profile |
Branded contrast agents typically enjoy gross margins exceeding 70% |
5.3 Investment Considerations
| Opportunity |
Risks |
Mitigation |
| Expansion into emerging markets |
Regulatory delays |
Strategic partnerships with local firms |
| Developing new indications or formulations |
R&D costs |
Leveraging existing infrastructure |
| Market penetration via clinical guidelines |
Competition |
Demonstrating superior imaging outcomes |
6. Comparison with Alternative Imaging Solutions
| Attribute |
EOVIST |
Gadavist |
Multihance |
Non-gadolinium agents (e.g., Microbubbles) |
| Specificity |
Hepatocyte-specific |
General |
General |
Organ-specific, non-enhanced |
| Safety Profile |
Safe, with low adverse events |
Very safe |
Safe |
Variable, especially in renal impairment |
| Regulatory Approvals |
US, EU, Japan |
Worldwide |
Widely approved |
Emerging, region-specific |
Implication: EOVIST's niche benefits differentiate it for precise hepatic imaging, though broader market competition exists.
7. Market Entry and Expansion Strategies
| Strategy |
Implementation Steps |
Potential Outcomes |
| Geographic Expansion |
Registration in China, India |
Increased revenue streams |
| Clinical Education |
Awareness campaigns, training |
Higher adoption rates |
| Pipeline Development |
New indications, formulations |
Diversification and growth |
| Partnerships & Alliances |
Collaborate with local distributors |
Faster market access |
8. Regulatory and Policy Trends Impacting EOVIST
| Trend |
Impact |
Examples/References |
| Value-based Healthcare |
Justifies premium pricing |
US MACRA, Europe HTA processes |
| Digital Imaging Integration |
Enhanced Market Penetration |
AI-enabled diagnostics |
| Personalized Medicine |
Tailored use of contrast agents |
Stratified imaging approaches |
9. Key Market Risks
| Risk |
Potential Impact |
Mitigation Strategies |
| Regulatory Delays |
Sales stagnation |
Engage early with regulators |
| Competitive Innovations |
Market share erosion |
Focus on differentiation and clinical data |
| Reimbursement Constraints |
Reduced profitability |
Demonstrate clinical and economic value |
| Supply Chain Disruptions |
Product availability |
Diversify manufacturing bases |
10. Conclusions and Investment Outlook
EOVIST occupies a specialized segment in hepatic MRI imaging, with steady growth driven by increasing liver disease prevalence, technological advancements, and clinical preferences for hepatocyte-specific agents. Its current market share remains moderate but poised for expansion—particularly within emerging markets and through pipeline development.
While competition from broad-spectrum and non-gadolinium contrast agents persists, EOVIST’s high specificity and clinical utility support a resilient positioning. Strategic expansion via regulatory approvals, partnerships, and clinical education will be critical to capitalize on its growth potential.
Key Takeaways
- Market position: Niche but stable, with growth prospects tied closely to liver disease epidemiology.
- Revenue potential: Projected to grow at approximately 5-6% CAGR over next five years.
- Competitive edge: Superior lesion characterization provides differentiation.
- Investment risk: Regulatory delays, competitive innovations, and reimbursement policies pose ongoing challenges.
- Strategic focus: International market growth, pipeline expansion, and clinical differentiation are essential for maximizing valuation.
5 Unique FAQs
Q1. How does EOVIST compare to other hepatic imaging agents in terms of clinical efficacy?
EOVIST has demonstrated superior sensitivity in detecting and characterizing liver lesions, especially small hepatocellular carcinomas, due to its hepatocyte-specific uptake. Clinical studies support its higher diagnostic accuracy compared to non-specific contrast agents.
Q2. What are the major regulatory hurdles for expanding EOVIST's market presence?
Regulatory hurdles include achieving approval in emerging markets like China and India, aligning with local health standards, and addressing evolving data requirements from agencies like the FDA and EMA. Early engagement and local collaborations can mitigate delays.
Q3. What is the outlook for reimbursement and pricing in developed vs. developing countries?
In developed countries, reimbursement is favorable if clinical benefits are demonstrated and outcomes are improved. In developing countries, price sensitivity and budget constraints limit reimbursement levels, necessitating cost-effective pricing strategies.
Q4. How does the competitive landscape affect EOVIST’s growth strategy?
Intense competition from broad-spectrum agents and non-contrast methods necessitates emphasizing its clinical advantages, developing complementary indications, and fostering partnerships for market expansion.
Q5. Are there ongoing R&D efforts to expand EOVIST's application beyond hepatic imaging?
Currently, research focuses on optimized dosages and combination protocols. No significant pipelines target non-hepatic applications, indicating a strategic focus on its core indication with incremental improvements.
References
[1] MarketsandMarkets. (2022). Contrast Agents Market.
[2] World Health Organization. (2021). Global prevalence of liver disease.
